Abstract
Immune checkpoint inhibitors (ICI) have revolutionised cancer treatment, resulting in long-term durable responses. In advanced disease, ICIs are administered every 2-6 weeks i.v. until cancer progression or unacceptable toxicity, which is often several years’ treatment. Physiological efficacy of anti-PD-1 antibodies (maximal receptor occupancy) is seen at lower doses than those in routine use. Pharmacodynamic studies indicate sustained target occupancy of >70% for at least 2 months, despite half-lives of 2-3 weeks.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
